CureVac NV (CVAC)

CureVac NV (CVAC)

Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

CureVac NV (CVAC) Profile

CureVac N.V., a clinical-stage biopharmaceutical firm, is focused on the development of a diverse range of revolutionary therapies based on messenger ribonucleic acid (mRNA). It is working to develop prophylactic vaccines, including CV7202, a prophylactic mRNA-based vaccine candidate against COVID-19; a vaccine for lassa yellow fever; a vaccine for the respiratory syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and immunisations against Rota, malaria, and universal influenza. Additionally, the company is developing RNA-based cancer immunotherapies, comprising ofCV8102 (BI 1361849), a self-adjuvanting mRNA vaccine in Phase 1 clinical trials for non-small cell lung cancer, and also tumour-associated antigens and shared neo-antigens. Additionally, the company is developing protein-based therapeutics for Cas9 gene editing, ophthalmic and respiratory illnesses, as well as therapeutic antibodies. The headquarters of the corporation are in T14 Bingen, Germany. Full Time Employees: 455 latest stock price29.860.00 (0.00%) At close: 04:00 PM as at 1/12/2022 EST. Market cap 5,585B USD. CureVac total assets for the quarter ending September 30, 2021, were $1.588B.

CureVac NV (CVAC.xnas) News
CureVac is developing CV2CoV, a preclinical second-generation mRNA vaccine potential, against SARS-CoV-2 in partnership with GlaxoSmithKline Plc (NYSE: GSK). In Q1 2022, the business plans to initiate a Phase 1 trial evaluating CV2CoV.

Holding cost
Trading hours in US Eastern Time
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30

Start Trading CureVac NV (CVAC)
with a Market Leader Today

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

6 Reasons to Trade Share
CFDs with FP Markets

An Australian-regulated
forex & CFD broker

Go Long or Short

Increase your ability to profit in all market conditions Leverage options up to 20:1

Direct Market Access (DMA) Execution

Real-time, transparent share prices Control, Functionality and deep liquidity Full Market depth & see your orders in the queue

Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with superior client portal

24/5 Multilingual
Customer Support

Award winning support & personal account managers

Global Exposure

Low margins and competitive commission +10,000 products on global stocks across 4 continents

Earn Dividends

On long positions No ownership of physical shares necessary

Start Trading
in Minutes

Open an account now

bullet Access 10,000+ financial instruments
bullet Auto open & close positions
bullet News & economic calendar
bullet Technical indicators & charts
bullet Many more tools included

By supplying your email you agree to FP Markets privacy policy and receive future marketing materials from FP Markets. You can unsubscribe at any time.

Get instant Updates in Telegram
Sitemap | © FP Markets 2022